SCHEMBL910401

SCHEMBL910401

[CH2]C(C)(N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL8854303 0.79
SCHEMBL27928856 0.79
SCHEMBL23000921 0.79
SCHEMBL11256487 0.77
SCHEMBL29956233 0.77
SCHEMBL93580 0.77
SCHEMBL31421734 0.77
SCHEMBL128632 0.77
SCHEMBL4648822 0.77
SCHEMBL23312 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0865792-A1 Pharmaceutical composition containing immunoglobulin for topical use ROTKREUZSTIFTUNG ZENTRALLABORATORIUM BLUTSPENDEDIENST SRK (CH) 1998-09-23 EP claimed
CN-114213236-A Synthesis of Yeast dehydrogenase inhibitors 上海寻科生物医药科技有限公司 2022-03-22 CN disclosed
US-20120093896-A1 USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS CIBA CORPORATION (US) 2012-04-19 US disclosed
US-7871642-B2 Use of nanodispersions in pharmaceutical end formulations CIBA SPECIALTY CHEMICALS CORPORATION (US) 2011-01-18 US disclosed
EP-2170250-A1 USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS BASF SE (DE) 2010-04-07 EP disclosed
WO-2009016064-A1 USE OF NANODISPERSIONS TO PROTECT WATER-SOLUBLE INGREDIENTS IN COSMETIC END FORMULATIONS BASF SE (CH) 2009-02-05 WO disclosed
EP-2000131-A2 Method for applying an active ingredient to a substrate, compositions for said method, receptacle containing a composition and use of said compositions VESIFACT AG (CH) 2008-12-10 EP disclosed
EP-1385478-B1 METHOD FOR APPLYING AN ACTIVE INGREDIENT TO A SUBSTRATE, COMPOSITIONS FOR SAID METHOD, CONTAINER CONTAINING A COMPOSITION AND USE OF SAID COMPOSITIONS VESIFACT AG (CH) 2008-10-15 EP disclosed
US-7381423-B2 Use of nanodispersions in cosmetic end formulations CIBA SPECIALTY CHEMICALS CORP. (US) 2008-06-03 US disclosed
US-20060292191-A1 Use of nanodispersions in pharmaceutical end formulations CIBA SPECIALITY CHEMICALS CORP. 2006-12-28 US disclosed
US-5658898-A CONTAINING SPARINGLY WATER SOLUBLE STAUROSPORIN DERIVATIVE, PURE PHOSPHOLIPID, TRIGLYCERIDE, PARTIAL FATTY ACID ESTER OF POLYOXYETHYLENE SORBITAN, WATER CIBA GEIGY CORPORATION (US) 1997-08-19 US disclosed
WO-1997021428-A1 CORTISONE SPRAY FOR TOPICAL ADMINISTRATION VESIFACT AG (CH) 1997-06-19 WO disclosed
WO-1996037192-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SPHINGO- AND GLYCOLIPIDS VESIFACT AG (CH) 1996-11-28 WO disclosed
EP-0733372-A2 Pharmaceutical base for the formulation of nanosuspensions CIBA-GEIGY AG (CH) 1996-09-25 EP disclosed
EP-0733358-A2 Nanosuspensions for intravenous application CIBA-GEIGY AG (CH) 1996-09-25 EP disclosed
EP-0711557-A1 Base for formulating pharmaceutical agents CIBA-GEIGY AG (CH) 1996-05-15 EP disclosed
EP-0711556-A1 Intravenous solutions containing staurosporine derivatives CIBA-GEIGY AG (CH) 1996-05-15 EP disclosed
US-5356888-A Elastase inhibitors FARMITALIA CARLO ERBA (IT) 1994-10-18 US disclosed
EP-0616801-A1 Process for preparing a liposome dispersion at high pressure CIBA-GEIGY AG (CH) 1994-09-28 EP disclosed
EP-0467838-A2 Process for preparing an injectable liposome dispersion CIBA-GEIGY AG (CH) 1992-01-22 EP disclosed